Salivary Immunosuppressive Cytokines IL-10 and IL-13 Are Significantly Elevated in Oral Squamous Cell Carcinoma Patients

REFERENCES

• Elledge ROC, Khazaee-Farid R, Walker RJ, Sundaram K, Monaghan A. A library-based ecological study to investigate the contribution of ethnicity to the incidence of oral cancer within health authorities in England and Wales. Br J Oral Maxillofac Surg 2011;49(1):42–46.
   PubMed Web of Science ®Google Scholar
• de Camargo Cancela M, Voti L, Guerra-Yi M, Chapuis F, Mazuir M, Curado MP. Oral cavity cancer in developed and in developing countries: population-based incidence. Head Neck 2010;32(3):357–367.
   PubMed Web of Science ®Google Scholar
• Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. CA Cancer J Clin 2011;61(2):69–90.
   PubMed Web of Science ®Google Scholar
• Warnakulasuriya S. Living with oral cancer: epidemiology with particular reference to prevalence and life-style changes that influence survival. Oral Oncol 2010;46(6):407–410.
   PubMed Web of Science ®Google Scholar
• Negus R, Balkwill F. Cytokines in tumour growth, migration and metastasis. World J Urol 1996;14(3):157–165.
   PubMed Web of Science ®Google Scholar
• Ben-Baruch A. Inflammation-associated immune suppression in cancer: the roles played by cytokines, chemokines and additional mediators. Semin Cancer Biol 2006;16(1):38–52.
   PubMed Web of Science ®Google Scholar
• Dunlop RJ, Campbell CW. Cytokines and advanced cancer. J Pain Symptom Manage 2000;20(3):214–232.
   PubMed Web of Science ®Google Scholar
• Terabe M, Park JM, Berzofsky JA. Role of IL-13 in regulation of anti-tumor immunity and tumor growth. Cancer Immunol Immunother 2004;53(2):79–85.
   PubMed Web of Science ®Google Scholar
• Fallon PG, Jolin HE, Smith P, Emson CL, Townsend MJ, Fallon R, Smith P, McKenzie AN. IL-4 induces characteristic Th2 responses even in the combined absence of IL-5, IL-9, and IL-13. Immunity 2002;17(1):7–17.
   PubMed Web of Science ®Google Scholar
• Jager A, Sleijfer S, van der Rijt CCD. The pathogenesis of cancer related fatigue: could increased activity of pro-inflammatory cytokines be the common denominator? Eur J Cancer 2008;44(2):175–181.
   PubMed Web of Science ®Google Scholar
• Chen Z, Malhotra PS, Thomas GR, Ondrey FG, Duffey DC, Smith CW, Enamorado I, Yeh NT, Kroog GS, Rudy S, McCullagh L, Mousa S, Quezado M, Herscher LL, Van Waes C . Expression of proinflammatory and proangiogenic cytokines in patients with head and neck cancer. Clin Cancer Res 1999;5(6):1369–1379.
   PubMed Web of Science ®Google Scholar
• Hazelbag S, Fleuren GJ, Baelde JJ, Schuuring E, Kenter GG, Gorter A. Cytokine profile of cervical cancer cells. Gynecol Oncol 2001;83(2):235–243.
   PubMed Web of Science ®Google Scholar
• Azizi G, Mirshafiey A. The potential role of proinflammatory and antiinflammatory cytokines in Alzheimer disease pathogenesis. Immunopharmacol Immunotoxicol 2012;34(6):881–895.
   PubMed Web of Science ®Google Scholar
• Vezzani A, Moneta D, Richichi C, Aliprandi M, Burrows SJ, Ravizza T, Perego C, De Simoni MD. Functional role of inflammatory cytokines and antiinflammatory molecules in seizures and epileptogenesis. Epilepsia 2002;43(s5):30–35.
   PubMedGoogle Scholar
• Khandavilli SD, Ceallaigh PÓ, Lloyd CJ, Whitaker R. Serum C-reactive protein as a prognostic indicator in patients with oral squamous cell carcinoma. Oral Oncol 2009;45(10): 912–914.
   PubMed Web of Science ®Google Scholar
• Czerninski R, Basile J, Kartin-Gabay T, Laviv A, Barak V. Cytokines and tumor markers in potentially malignant disorders and oral squamous cell carcinoma: a pilot study. Oral Dis 2014;20(5):477–481.
   PubMed Web of Science ®Google Scholar
• Chang K-P, Wu C-C, Fang K-H, Tsai C-Y, Chang Y-L, Liu S-C, Kao H-K. Serum levels of chemokine (C-X-C motif) ligand 9 (CXCL9) are associated with tumor progression and treatment outcome in patients with oral cavity squamous cell carcinoma. Oral Oncol 2013;49(8):802–807.
   PubMed Web of Science ®Google Scholar
• Elashoff D, Zhou H, Reiss J, Wang J, Xiao H, Henson B, Hu S, Arellano M, Sinha U, Le A, Messadi D, Wang M, Nabili V, Lingen M, Morris D, Randolph T, Feng Z, Akin D, Kastratovic DA, Chia D, Abemayor E, Wong DT. Prevalidation of salivary biomarkers for oral cancer detection. Cancer Epidemiol Biomarkers Prev 2012;21(4):664–672.
   PubMed Web of Science ®Google Scholar
• Arellano-Garcia ME, Hu S, Wang J, Henson B, Zhou H, Chia D, Wong DT. Multiplexed immunobead-based assay for detection of oral cancer protein biomarkers in saliva. Oral Dis 2008;14(8):705–712.
   PubMed Web of Science ®Google Scholar
• Korostoff A, Reder L, Masood R, Sinha UK. The role of salivary cytokine biomarkers in tongue cancer invasion and mortality. Oral Oncol 2011;47(4):282–287.
   PubMed Web of Science ®Google Scholar
• Liu J, Duan Y. Saliva: a potential media for disease diagnostics and monitoring. Oral Oncol 2012;48(7):569–577.
   PubMed Web of Science ®Google Scholar
• Pindborg JJ, Reichart P, Smith C, van der Waal I. Definitions and explanatory notes. In Histological Typing of Cancer and Precancer of the Oral Mucosa. Berlin: Springer, 1997, 11–31.
   Google Scholar
• Costa NL, Valadares MC, Souza PPC, Mendonça EF, Oliveira JC, Silva TA, Batista AC. Tumor-associated macrophages and the profile of inflammatory cytokines in oral squamous cell carcinoma. Oral Oncol 2013;49(3):216–223.
   PubMed Web of Science ®Google Scholar
• Tepper RI, Pattengale PK, Leder P. Murine interleukin-4 displays potent anti-tumor activity in vivo. Cell 1989;57(3):503–512.
   PubMed Web of Science ®Google Scholar
• Volpert OV, Fong T, Koch AE, Peterson JD, Waltenbaugh C, Tepper RI, Bouck NP. Inhibition of angiogenesis by interleukin 4. J Exp Med 1998;188(6):1039–1046.
   PubMed Web of Science ®Google Scholar
• Conticello C, Pedini F, Zeuner A, Patti M, Zerilli M, Stassi G, Messina A, Peschle C, De Maria R. IL-4 protects tumor cells from anti-CD95 and chemotherapeutic agents via up-regulation of antiapoptotic proteins. J Immunol 2004;172(9):5467–5477.
   PubMed Web of Science ®Google Scholar
• Ma HL, Whitters MJ, Jacobson BA, Donaldson DD, Collins M, Dunussi-Joannopoulos K. Tumor cells secreting IL-13 but not IL-13Ralpha2 fusion protein have reduced tumorigenicity in vivo. Int Immunol 2004;16(7):1009–1017.
   PubMed Web of Science ®Google Scholar
• Terabe M, Matsui S, Noben-Trauth N, Chen H, Watson C, Donaldson DD, Carbone DP, Paul WE, Berzofsky JA. NKT cell-mediated repression of tumor immunosurveillance by IL-13 and the IL-4R-STAT6 pathway. Nat Immunol 2000;1(6):515–520.
   PubMed Web of Science ®Google Scholar
• Kaskas NM, Moore-Medlin T, McClure GB, Ekshyyan O, Vanchiere JA, Nathan CA. Serum biomarkers in head and neck squamous cell cancer. JAMA Otolaryngology–Head Neck Sur 2014;140(1):5–11.
   Web of Science ®Google Scholar
• Hamzavi M, Tadbir AA, Rezvani G, Ashraf MJ, Fattahi MJ, Khademi B, Sardari Y, Jeirudi N. Tissue expression, serum and salivary levels of IL-10 in patients with head and neck squamous cell carcinoma. Asian Pac J Cancer Prev 2013;14(3):1681–1685.
   PubMed Web of Science ®Google Scholar
• Woodford D, Johnson SD, De Costa AM, Young MR. An inflammatory cytokine milieu is prominent in premalignant oral lesions, but subsides when lesions progress to squamous cell carcinoma. J Clin Cell Immunol 2014;5(3).
   Google Scholar
• Formentini A, Prokopchuk O, Strater J, Kleeff J, Grochola LF, Leder G, Henne-Bruns D, Korc M, Kornmann M. Interleukin-13 exerts autocrine growth-promoting effects on human pancreatic cancer, and its expression correlates with a propensity for lymph node metastases. Int J Colorectal Dis 2009;24(1):57–67.
   PubMed Web of Science ®Google Scholar
• Prokopchuk O, Liu Y, Henne-Bruns D, Kornmann M. Interleukin-4 enhances proliferation of human pancreatic cancer cells: evidence for autocrine and paracrine actions. Br J Cancer 2005;92(5):921–928.
   PubMed Web of Science ®Google Scholar
• Kanai T, Watanabe M, Hayashi A, Nakazawa A, Yajima T, Okazawa A, Yamazaki M, Ishii H, Hibi T. Regulatory effect of interleukin-4 and interleukin-13 on colon cancer cell adhesion. Br J Cancer 2000;82(10):1717–1723.
   PubMed Web of Science ®Google Scholar
• Chen CJ, Sung WW, Su TC, Chen MK, Wu PR, Yeh KT, Ko JL, Lee H. High expression of interleukin 10 might predict poor prognosis in early stage oral squamous cell carcinoma patients. Clin Chim Acta 2013;415:25–30.
   PubMed Web of Science ®Google Scholar
• Chuang CY, Sung WW, Wang L, Lin WL, Yeh KT, Su MC, Hsin CH, Lee SY, Wu BC, Cheng YW, Lee H. Differential impact of IL-10 expression on survival and relapse between HPV16-positive and -negative oral squamous cell carcinomas. PLoS One 2012;7(10):e47541.
   PubMed Web of Science ®Google Scholar
• Alhamarneh O, Agada F, Madden L, Stafford N, Greenman J. Serum IL10 and circulating CD4(+) CD25(high) regulatory T cell numbers as predictors of clinical outcome and survival in patients with head and neck squamous cell carcinoma. Head Neck 2011;33(3):415–423.
   PubMed Web of Science ®Google Scholar
• Vairaktaris E, Yapijakis C, Serefoglou Z, Avgoustidis D, Critselis E, Spyridonidou S, Vylliotis A, Derka S, Vassiliou S, Nkenke E, Patsouris E. Gene expression polymorphisms of interleukins-1 beta, -4, -6, -8, -10, and tumor necrosis factors-alpha, -beta: regression analysis of their effect upon oral squamous cell carcinoma. J Cancer Res Clin Oncol 2008;134(8):821–832.
   PubMed Web of Science ®Google Scholar
• Vairaktaris E, Yapijakis C, Serefoglou Z, Derka S, Vassiliou S, Nkenke E, Vylliotis A, Spyridonidou S, Neukam SW, Schlegel KA, Patsouris E. The interleukin-10 (-1082A/G) polymorphism is strongly associated with increased risk for oral squamous cell carcinoma. Anticancer Res 2008;28(1A):309–314.
   PubMed Web of Science ®Google Scholar
• Arend WP. Interleukin-1 receptor antagonist: discovery, structure and properties. Prog Growth Factor Res 1990;2(4):193–205.
   PubMedGoogle Scholar
• Dubost JJ, Perrier S, Afane M, Viallard JL, Roux‐Lombard P, Baudet‐Pommel M, Begue C, Kemeny JL, Sauvezie B. IL‐1 receptor antagonist in saliva; characterization in normal saliva and reduced concentration in Sjo‥ gren's syndrome (SS). Clin Exp Immunol 1996;106(2):237–242.
   PubMed Web of Science ®Google Scholar
• Linkov F, Lisovich A, Yurkovetsky Z, Marrangoni A, Velikokhatnaya L, Nolen B, Winans M, Bigbee W, Siegfried J, Lokshin A, Ferris RL. Early detection of head and neck cancer: development of a novel screening tool using multiplexed immunobead-based biomarker profiling. Cancer Epidemiol Biomarkers Prev 2007;16(1):102–107.
   PubMed Web of Science ®Google Scholar
• Singer CF, Kronsteiner N, Marton E, Walter I, Kubista M, Czerwenka K, Schreiber M, Tschugguel W, Wieser F, Kubista E. Interleukin-1 system and sex steroid receptor gene expression in human endometrial cancer. Gynecol Oncol 2002;85(3):423–430.
   PubMed Web of Science ®Google Scholar
• Van Le L, Haskill S, Jaffe GJ, Fowler WC, Jr. Expression of interleukin-1 and interleukin-1 receptor antagonists in endometrial cancer. Gynecol Oncol 1991;42(2):161–164.
   PubMed Web of Science ®Google Scholar
• Smith DR, Kunkel SL, Standiford TJ, Chensue SW, Rolfe MW, Orringer MB, Whyte RI, Burdick MD, Danforth JM, Gilbert AR, Strieter RM. The production of interleukin-1 receptor antagonist by human bronchogenic carcinoma. Am J Pathol 1993;143(3):794–803.
   PubMed Web of Science ®Google Scholar
• Oelmann E, Kraemer A, Serve H, Reufi B, Oberberg D, Patt S, Herbst H, Stein H, Thiel E, Berdel WE. Autocrine interleukin-1 receptor antagonist can support malignant growth of glioblastoma by blocking growth-inhibiting autocrine loop of interleukin-1. Int J Cancer 1997;71(6):1066–1076.
   PubMed Web of Science ®Google Scholar
• Iizuka N, Hazama S, Hirose K, Abe T, Tokuda N, Fukumoto T, Tangoku A, Oka M. Interleukin-1 receptor antagonist mRNA expression and the progression of gastric carcinoma. Cancer Lett 1999;142(2):179–184.
   PubMed Web of Science ®Google Scholar
• Fujiwaki R, Hata T, Miyazaki K, Kawamura T, Inada K. Elevation of serum interleukin-1 receptor antagonist levels in women with gynaecological cancers. Br J Obstet Gynaecol 1997;104(12):1407–1408.
   PubMedGoogle Scholar
• Fujiwaki R, Iida K, Nakayama K, Kanasaki H, Hata K, Katabuchi H, Okamura H, Miyazaki K. Clinical significance of interleukin-1 receptor antagonist in patients with cervical carcinoma. Gynecol Oncol 2003;89(1):77–83.
   PubMed Web of Science ®Google Scholar
• Rutkowski P, Kaminska J, Kowalska M, Ruka W, Steffen J. Cytokine and cytokine receptor serum levels in adult bone sarcoma patients: correlations with local tumor extent and prognosis. J Surg Oncol 2003;84(3):151–159.
   PubMed Web of Science ®Google Scholar
• Graziano F, Ruzzo A, Canestrari E, Loupakis F, Santini D, Rulli E, Humar B, Galluccio N, Bisonni R, Floriani I, Maltese P, Falcone A, Tonini G, Catalano V, Fontana A, Giustini L, Masi G, Vincenzi B, Alessandroni P, Magnani M. Variations in the interleukin-1 receptor antagonist gene impact on survival of patients with advanced colorectal cancer. Pharmacogenomics J 2009;9(1):78–84.
   PubMed Web of Science ®Google Scholar
• Mustea A, Pirvulescu C, Konsgen D, Braicu EI, Yuan S, Sun P, Lichtenegger W, Sehouli J. Decreased IL-1 RA concentration in ascites is associated with a significant improvement in overall survival in ovarian cancer. Cytokine 2008;42(1): 77–84.
   PubMed Web of Science ®Google Scholar
• Rathakrishnan A, Wang SM, Hu Y, Khan AM, Ponnampalavanar S, Lum LC, Manikam R, Sekaran SD. Cytokine expression profile of dengue patients at different phases of illness. PLoS One 2012;7(12):e52215.
   PubMed Web of Science ®Google Scholar
• Bomert M, Kollisch G, Roponen M, Lauener R, Renz H, Pfefferle PI, Al-Fakhri N. Analytical performance of a multiplexed, bead-based cytokine detection system in small volume samples. Clin Chem Lab Med 2011;49(10):1691–1693.
   PubMed Web of Science ®Google Scholar
• de Jager W, te Velthuis H, Prakken BJ, Kuis W, Rijkers GT. Simultaneous detection of 15 human cytokines in a single sample of stimulated peripheral blood mononuclear cells. Clin Diagn Lab Immunol 2003;10(1):133–139.
   PubMedGoogle Scholar
• Zhang X, Junior CR, Liu M, Li F, D'Silva NJ, Kirkwood KL. Oral squamous carcinoma cells secrete RANKL directly supporting osteolytic bone loss. Oral Oncol 2013;49(2):119–128.
   PubMed Web of Science ®Google Scholar
• Pries R, Wollenberg B. Cytokines in head and neck cancer. Cytokine Growth Factor Rev 2006;17(3):141–146.
   PubMed Web of Science ®Google Scholar
• Schapher M, Wendler O, Groschl M. Salivary cytokines in cell proliferation and cancer. Clin Chim Acta 2011;412 (19–20):1740–1748.
   PubMed Web of Science ®Google Scholar